Opthea Reported A Drop Of 11.6% In Revenue During FY2020

Opthea Limited (ASX:OPT) has released its FY2020 results and reported a fall in its revenue by 11.6% to A$808,405. Loss from the ordinary activities which was A$20,910,061 in FY2019 decreased to A$16,529,281 in FY20.

The major expenses during the period was related to R&D, especially costs related to the Phase 2b and Phase1b/2a clinical trials of OPT?302 for wet AMD and DME. Direct R&D expenses amounted to A$17,954,073.

Moreover, OPT received an R&D tax incentive payment of A$14,636,973 during FY2020.

At AEST 12:06 PM, OPT shares we trading at $2.510, up by 0.803%.





Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK